We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Comparison Study With E-DO in Chronic Hand Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00556855
Recruitment Status : Completed
First Posted : November 12, 2007
Last Update Posted : January 12, 2009
Information provided by:

Study Description
Brief Summary:
The objective of this study is to evaluate the topical E-DO in patients with Chronic Hand Dermatitis (fu kuei shou).

Condition or disease Intervention/treatment
Chronic Hand Dermatitis Other: E-DO Other: Placebo

Detailed Description:

Hand dermatitis, also called fu kuei shou, is a skin condition in which the hands develop a rash and become red, dry, cracked, and inflamed. This is a very common occuring in about 10% of women and 4% of men. The condition can eventually cause pain on contact with even simple solutions such as water. Hand dermatitis is particularly common in industries involving cleaning, catering, metalwork, hairdressing, healthcare and mechanical work, and is often difficult to be treated effectively. Some patients develop varying levels of disability due to lack of acceptable effective treatments and may be forced to change occupations in order to achieve relief.

Primary treatment for hand dermatitis is typically topical corticosteroids, especially when the offending agent(s) cannot be identified or avoided. However, patients may eventually develop tachyphylaxis to the anti-inflammatory activity of mid-potency or high-potency topical corticosteroids and patients with severe, chronic involvement may often be less likely to respond. Potential topical alternatives to corticosteroids include psoralen plus ultraviolet (PUVA), but the phototherapies are inconvenient because multiple clinical visits are required and hand phototherapy units may not be available.

Moisturizers have been found to help restore the skin barrier providing a protective layer on surface of the skin to trap water and prevent the penetration of irritants and allergens. An emollient cream is superior in trapping the moisture within the skin. Emollients may form a covering film, which acts as a barrier for chemicals from the exterior and which restricts the loss of water and other essential substances from the interior. E-DO gel is a potential agent for revitalizing our skin cells so that regain their moisture retention capacity.

E-DO has known significant improvements in wound healing and the inhibition of Staphylococcus aureus and Propionibacterium acnes. This pilot research trial will investigate the effect of topical E-DO for patients with hand dermatitis.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 67 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 4-Week Randomized, Double-Blind, Placebo-Controlled, Right-Left Comparison Study With E-DO in Chronic Hand Dermatitis
Study Start Date : December 2007
Primary Completion Date : July 2008
Study Completion Date : July 2008
Arms and Interventions

Arm Intervention/treatment
Experimental: A
applied on one hand
Other: E-DO
topical lotion, once daily (evening), total duration: 4 weeks
Other Name: HK-03
Placebo Comparator: B
applied on the other hand
Other: Placebo
topical lotion, once daily (evening), total duration: 4 weeks
Other Name: Vehicle

Outcome Measures

Primary Outcome Measures :
  1. The therapeutic response rate (clear or almost clear) base on Investigator Global Assessment (IGA) [ Time Frame: at Week 4 (or at time of early discontinuation) ]

Secondary Outcome Measures :
  1. The proportion of the patients with at least 50% improvement (clinically significant response) base on the patient's global assessment (PaGA) [ Time Frame: at Week 4 (or at time of early discontinuation) ]
  2. The percent change in the HEAS (Hand Eczema Area and Severity Score) from baseline to post-treatment. [ Time Frame: during 4 Weeks ]
  3. The change of pruritus score and pain score from baseline to post-treatment [ Time Frame: during 4 weeks ]
  4. The change in the degree of moisture on the skin's surface, and the water evaporation on skin surfaces by TEWL, and the QOL scores from baseline to the end of study. [ Time Frame: End of study (4 weeks) ]
  5. The safety and tolerability of E-DO including AE/SAE report [ Time Frame: during 4 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females aged 20 years of age or above;
  • Patients must have chronic hand dermatitis based upon clinical diagnosis at least mild dermatitis of the both hands at baseline, as defined by an Investigator Global Assessment score of 2 (mild) to 5 (very severe);
  • Patients must have been informed of the study procedures and therapies and have given their written informed consent.

Exclusion Criteria:

  • Women who are pregnant or who are breast-feeding;
  • Patients who have received systemic corticosteroids (i.e., oral, intravenous, intra-articular, rectal, intramuscular) within one month prior to first application of study medication;
  • Patients who have received phototherapy (e.g., UVB, PUVA) or systemic therapy (e.g., immunosuppressants, cytostatics) known or suspected to have an effect on hand dermatitis within one month prior to first application of study medication;
  • Patients who are treated with topical therapy (e.g., tar, topical corticosteroids) known or suspected to have an effect on hand dermatitis within 7 days prior to first application of study medication;
  • Patients who have a diagnosis on the hands of active atopic dermatitis, dyshidrotic eczema, psoriasis, urticaria, active fungal or bacterial infection, or identified allergic contact dermatitis (e.g., poison ivy dermatitis)
  • Patients with hypersensitivity to vitamin B, vitamin C, vitamin E, beta-carotene.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00556855

Department of Dermatology, NTUH
Taipei, Taiwan, 100
Sponsors and Collaborators
HenKan Pharmaceutical Co., Ltd.
Principal Investigator: Chia-Yu Chu, MD, PhD Department of Dermatology, Nation Taiwan University Hopital, R.O.C.
More Information

Responsible Party: Joseph Tseng, HenKan Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT00556855     History of Changes
Other Study ID Numbers: EDO-CHD001
First Posted: November 12, 2007    Key Record Dates
Last Update Posted: January 12, 2009
Last Verified: January 2009

Keywords provided by HenKan Pharmaceutical Co., Ltd.:
chronic hand dermatitis
research study

Additional relevant MeSH terms:
Skin Diseases